The Journal of Pediatrics
Volume 150, Issue 4 , Pages 338-344.e1 , April 2007

Treatment with Rituximab in Benign and Malignant Hematologic Disorders in Children

  • Lisa B. Giulino, MD

      Affiliations

    • Weill Medical College of Cornell University, Department of Pediatrics, Division of Hematology/Oncology, New York, NY
    • ,
  • James B. Bussel, MD

      Affiliations

    • Weill Medical College of Cornell University, Department of Pediatrics, Division of Hematology/Oncology, New York, NY
    • Corresponding Author InformationReprint requests: Dr James B. Bussel, Weill Medical College of Cornell University, 525 East 68th Street, P-695, New York, NY 10021.
    • ,
  • Ellis J. Neufeld, MD, PhD

      Affiliations

    • Children’s Hospital Boston, Department of Pediatrics, Division of Hematology/Oncology, Boston, MA.
    • ,
  • Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network

Received 24 April 2006 ,Revised 4 October 2006 ,Accepted 13 December 2006.

References 

  1. Ballow M. -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?. J Allergy Clin Immunol. 2005;116:738–743
  2. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520–535
  3. Rituxan website; www.rituxan.com Accessed January 17, 2006.
  4. Remicade website; www.remicade.com Accessed January 17, 2006.
  5. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte–specific antigen. J Immunol. 1980;125:1678–1685
  6. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood. 1987;69:584–591
  7. O’Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48:125–132
  8. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121–1132
  9. Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem. 1995;270:13099–13104
  10. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445
  11. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–826
  12. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti–CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673–683
  13. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55–63
  14. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 2001;7:709–723
  15. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758
  16. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25:72–81
  17. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B-cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48:455–459
  18. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–5144
  19. Package insert: Rituxan (rituximab). San Diego, CA: IDEC Pharmaceuticals Corp; 2003;
  20. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–2164
  21. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232–239
  22. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13:1948–1950
  23. Wang J, Wiley J, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura (ITP) in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–221
  24. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642
  25. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–3274
  26. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000;27(6 suppl 12):37–41
  27. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, et al. French Pediatric-Onset SLE Study Group Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148:623–627
  28. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. [letter] Lancet. 2001;358:1511–1513
  29. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Israel Med Assoc J. 2002;4:1006–1008
  30. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861
  31. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–3997
  32. Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant. 2002;29:871–872
  33. Nowak-Wegrzyn A, King KE, Shirey RS, Chen AR, McDonough C, Lederman HM. Fatal warm autoimmune hemolytic anemia resulting from IgM autoagglutinins in an infant with severe combined immunodeficiency. J Pediatr Hematol Oncol. 2001;23:250–252
  34. Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J. Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory autoimmune haemolytic anaemia. Eur J Pediatr. 2001;160:492–496
  35. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002;116:465–467
  36. McMahon C, Babu L, Hodgson A, Hayat A, Connell NO, Smith OP. Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)? [letter]. Br J Haematol. 2002;117:480–483
  37. Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. [letter] Bone Marrow Transplant. 2002;29:365–366
  38. Corti P, Bonanomi S, Vallinoto C, Balduzzi A, Uderzo C, Cazzaniga G, et al. Rituximab for immune hemolytic anemia following T- and B-cell-depleted hematopoietic stem cell transplantation. Acta Haematol. 2003;109:43–45
  39. Ng PC, Lee KK, Lo AF, Li CK, Fok TF. Anti–B-cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child. 2003;88:337–339
  40. Kerridge I, Hann I, Ethel M, Potter M, Prentice HG. Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia. [letter] Intern Med J. 2003;33:544–545
  41. Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol. 2004;26:312–314
  42. Bonduel M, Zelazko M, Figueroa C, Magaldi G, Rossi J, del Pozo A. Successful treatment of autoimmune hemolytic anemia with rituximab in a child with severe combined immunodeficiency following nonidentical T-cell-depleted bone marrow transplantation. [letter] Bone Marrow Transplant. 2005;35:819–821
  43. Jubinsky PT, Rashid N. Successful treatment of a patient with mixed warm and cold antibody-mediated Evans syndrome and glucose intolerance. Pediatr Blood Cancer. 2005;45:347–350
  44. McMahon C, Babu L, Hodgson A, Hayat A, Connell NO, Smith OP. Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)?. [letter] Br J Haematol. 2002;117:480–483
  45. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925–2928
  46. Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. [letter] Haematologica. 2005;90:281–283
  47. Bengtson KL, Skinner MA, Ware RE. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr. 2003;143:670–673
  48. ten Cate R, Smiers FJ, Bredius RG, Lankester AC, van Suijlekom-Smit LW, Huizinga TW, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. [letter] Rheumatology. 2004;43:244
  49. Roganovic J. Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children. [letter] Eur J Pediatr. 2005;164:334
  50. Russo G, Licciardello M, La Spina M. Rituximab in children with idiopathic thrombocytopenic purpura: does it really work?. Eur J Pediatr. 2004;163:569
  51. Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, Bisogno G. Successful treatment with monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr. 2004;163:305–307
  52. Moschovi M, Trimis G, Pergantou H, Platokouki H, Vrachnou E, Tzortzatou-Stathopoulou F. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health. 2005;41:384–386
  53. Bengtson K, Skinner M, Ware R. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr. 2003;143:670–673
  54. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high-titre inhibitors. Haemophilia. 2006;12:218–222
  55. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol. 2004;125:366–368
  56. Mateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thromb Haemost. 2006;95:386–387
  57. Curry N, Stanworth S, Keeling D. The use of rituximab in two children with allo-antibodies towards factor VIII. [letter] Br J Haematol. 2006;133:214–216
  58. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100:3426–3428
  59. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424–4428
  60. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112–118
  61. Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O. Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus–associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr. 2002;34:389–393
  62. Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002;74:1000–1006
  63. Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol. 2006;30:328–336
  64. Quiros-Tejeira RE, Chang I, Karpen SJ, Bristow LJ, Scott JD, Goss JA. Post-transplant lymphoproliferative disease in pediatric liver transplant recipients treated with anti-CD20 monoclonal antibody: a long-term outcome study. J Pediatr Gastroenterol Nutr. 2004;39(suppl 1):S93
  65. Webber S, Harmon W, Faro A, Green M, Sarwal M, Hayashi R, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial [abstract]. Blood ?;104:213a.
  66. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. [letter] Lancet. 1998;352:1285
  67. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Blood. 2000;95:1502–1505
  68. Stachel DK, Schmid I, Schuster F, Stehr M, Baumeister FA, Muller-Hocker J. Lymphoproliferative syndrome in an infant after stem cell transplantation: successful therapy with T-lymphocytes and anti-CD20 monoclonal antibodies. Med Pediatr Oncol. 2000;35:503–505
  69. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab. Bone Marrow Transplant. 2001;27:329–332
  70. Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant. 2001;20:770–772
  71. Herman J, Vandenberghe P, van den Heuvel I, Van Cleemput J, Winnepenninckx V, Van Damme-Lombaerts R. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation. J Heart Lung Transplant. 2002;21:1304–1309
  72. Bueno J, Ramil C, Somoza I, Sanchez-Galindo A, Solar A, Arnal F, et al. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatr Transplant. 2003;7:153–156
  73. Al-Akash SI, Al Makadma AS, Al Omari MG. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant. 2005;9:249–253
  74. Zhu K, Chen J, Chen S. Treatment of Epstein-Barr virus–associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with rituximab following unrelated cord blood transplantation: case report and literature review. Hematology. 2005;10:365–370
  75. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005;20:1660–1663
  76. Gokce S, Suoglu OD, Sokucu S, Gun F, Emiroglu H, Celik A, et al. Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder. J Pediatr Gastroenterol Nutr. 2006;42:316–320
  77. Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, Bagni A, Pecorari M, et al. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases. Transplant Proc. 2005;37:2634–2635
  78. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11:113–116
  79. Choquet S, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Feremans W, et al. Multicenter, open-label, phase II trial to evaluate the efficacy and safety of treatment with rituximab in patients suffering from B-cell posttransplantation lymphoproliferative disorders (B-PTLD) (M39037 trial). Ann Oncol. 2002;13:37
  80. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003;9(10 pt 2):3945S–3952S
  81. Culic S, Culic V, Armanda V, Kuljis D, Pesutic-Pisac V, Jankovic S. Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Pediatr Hematol Oncol. 2003;20:339–344
  82. de Vries MJ, Veerman AJ, Zwaan CM. Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin’s lymphoma. [letter] Br J Haematol. 2004;125:414–415
  83. Okur FV, Oguz A, Karadeniz C, Citak C, Poyraz A, Boyunaga O. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt’s non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006;23:25–31
  84. Jetsrisuparb A, Wiangnon S, Komvilaisak P, Kularbkaew C, Yutanawiboonchai W, Mairieng E. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large-cell non-Hodgkin’s lymphoma. J Pediatr Hematol Oncol. 2005;27:223–226
  85. Imamura T, Yoshihara T, Morimoto A, Ishida H, Sugimoto T, Imashuku S. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma. Pediatr Hematol Oncol. 2006;23:19–24
  86. Corbacioglu S, Eber S, Gungor T, Hummerjohann J, Niggli F. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol. 2003;25:327–329
  87. Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, et al. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. [letter] Haematologica. 2006;91:272–273
  88. Kraal K, Schalij-Delfos N, van Buchem M, Egeler M, Ball L. Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab). Haematologica 2005(90 suppl):ECR24.
  89. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. [Review] [57 refs] [Journal Article. Research Support, Non-U.S. Gov’t. Review]. Annals of Internal Medicine. 2007;146:25–33

PII: S0022-3476(06)01204-2

doi: 10.1016/j.jpeds.2006.12.038

The Journal of Pediatrics
Volume 150, Issue 4 , Pages 338-344.e1 , April 2007

Article Tools